My view is $NWBO can make far more money by using current and future available capital to expand the deployment of the DCVax platform than by trying to make approximately 15% on the manufacturing of personalized therapies. This is because of the IP position the company has for both the manufacturing and theraputic entities. Vertically integrating the manufacturing "down the road" after the full deployment of the platform could be a possibility, but I believe that is > 5 years down the road. IMHO. Peace.
It’s all an attempt by some bears to try and make Advent a wedge issue between NWBio and its shareholders, to create distrust, and give the appearance of improprieties and conflict of interest by Linda Powers and NWBio
Fortunately, it’s a feeble last-ditch effort that will not work.
Market Data 
Markets 
AI
